The effect of continuous versus intermittent treatment with transdermal nitroglycerin on pacing-induced preconditioning in conscious rabbits

British Journal of Pharmacology
Z SzilvássyM Koltai

Abstract

1. Tolerance to the hypotensive effect of nitroglycerin (NG) blocks preconditioning induced by rapid ventricular pacing (RVP) in rabbits. In the present work the effect of continuous versus intermittent treatment with transdermal nitroglycerin on the pacing-induced preconditioning phenomenon was studied in conscious rabbits. 2. RVP (500 beats min-1 over 5 min) increased left ventricular end-diastolic pressure (LVEDP) from baseline 4.1 +/- 0.9 to postpacing 13.8 +/- 2.9 mmHg (P < 0.001) with a right intraventricular ST-segment elevation of 1.25 +/- 0.13 mV, two indicators of myocardial ischaemia. These changes were significantly attenuated when the RVP period was preceded by a preconditioning pacing of the same rate and duration with an interpacing interval of 5 min. 3. Protection by preconditioning was abolished when the animals had been made tolerant to the vasodilator effect of 30 micrograms kg-1 NG by the application of transdermal NG (approx. 0.07 mg kg-1 h-1) over 7 days. Furthermore, transdermal NG per se attenuated both RVP-induced ST-segment elevation and LVEDP-increase over the 7 day period. 4. With intermittent transdermal NG treatment (12 h 'patch on' vs 'patch off'), neither development of vascular tolerance nor att...Continue Reading

References

May 1, 1992·Cardiovascular Research·M S Marber, D M Yellon
Aug 1, 1987·The American Journal of Cardiology·J C CowanD G Julian
Sep 1, 1987·Journal of the American College of Cardiology·R LukeR Coxon
Apr 1, 1985·The American Journal of Cardiology·W C ReevesL Whitesell
Oct 1, 1983·Journal of Molecular and Cellular Cardiology·D J Hearse
Jul 1, 1984·The American Journal of Cardiology·J Abrams
Sep 1, 1984·The American Journal of Cardiology·J O Parker, H L Fung
Jul 1, 1980·Circulation Research·S WallensteinJ L Fleiss
Apr 1, 1995·Journal of Molecular and Cellular Cardiology·J R Parratt
Aug 1, 1994·British Journal of Pharmacology·Z SzilvassyM Koltai
May 1, 1993·Circulation·D G Harrison, J N Bates
Jan 1, 1996·Circulation Research·R SandhuG J Wilson
Dec 1, 1995·Journal of Molecular and Cellular Cardiology·Z SzilvassyM Koltai
Sep 30, 1996·Annals of the New York Academy of Sciences·P FerdinandyL Dux

❮ Previous
Next ❯

Citations

Sep 7, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Barna PeitlZoltán Szilvássy
Feb 3, 2012·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Monica LisiTommaso Gori
Sep 13, 2003·European Journal of Pharmacology·Tamás CsontPéter Ferdinandy
Jul 17, 1998·Trends in Pharmacological Sciences·P FerdinandyG F Baxter
Aug 24, 2012·Canadian Journal of Physiology and Pharmacology·Verónica D'AnnunzioRicardo J Gelpi
Jul 6, 2016·International Journal of Cardiology·Xavier Rossello, Derek M Yellon
Jan 5, 2000·European Journal of Clinical Investigation·P KovacsA Tosaki
Jul 19, 2011·Journal of Cardiovascular Pharmacology·Agnes BajzaZoltán Szilvássy
May 15, 2013·Journal of Cardiovascular Pharmacology·Veronika FeketeTamás Csont
Jan 30, 2015·Journal of Cardiovascular Pharmacology·Tamás CsontPéter Ferdinandy
May 18, 2011·Circulation·Thomas MünzelTommaso Gori
Nov 18, 2003·British Journal of Clinical Pharmacology·Katherine E FayersDavid W Laight
Dec 17, 2009·American Journal of Physiology. Heart and Circulatory Physiology·Tamás Csont
Apr 19, 2018·Basic Research in Cardiology·Derek M YellonSean M Davidson
Apr 13, 2004·Journal of Cardiovascular Pharmacology·Agnes BajzaZoltan Szilvassy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.